Research study Program year 2022 Source: CMS Open Payments

A Two-Part, Randomized, Double-Blind, Single-Dose, Crossover Study to

Research payments

$5,999,739

78 payments

Through program year 2022, $5,999,739 in research payments was reported against A Two-Part, Randomized, Double-Blind, Single-Dose, Crossover Study to, across 78 payments, paid by GlaxoSmithKline, LLC..

Paid by: GlaxoSmithKline, LLC.
ClinicalTrials.gov: No trial number was reported for this study

By program year

2 rows

Year	Kind	Amount	Payments
2022	Research	$218,693	3
2021	Research	$5,781,046	75

Breakdown

Who paid Research payments · program years 2021–2022

GlaxoSmithKline, LLC. $5,999,739 78 payments

Who received the money Research payments · program years 2021–2022

Ppd Development LP Organisation paid for research $1,661,684 18 payments
Ppd Development INC Clinics Organisation paid for research $1,661,684 18 payments
Altasciences Clinical Kansas PA Organisation paid for research $1,612,163 18 payments
Anaheim Clinical Trials Organisation paid for research $475,688 13 payments
Anaheim Clinical Trials LLC Organisation paid for research $369,827 8 payments
Ppd Organisation paid for research $218,693 3 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

5 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.